<p>波士顿，2025 年 12 月 15 日（环球新闻）—— Tiziana Life Sciences, Ltd.（纳斯达克：TLSA）（“Tiziana” 或 “公司”）是一家生物技术公司，正在开发突破性的免疫调节疗法，其主要开发候选药物为鼻用 foralumab，这是一种完全人源的抗 CD3 单克隆抗体。今天宣布其首席执行官 Ivor Elrifi 在公开市场购买了 163,400 股 Tiziana 普通股。这使得他目前购买的股票总数达到 357,848 股。</p>
<p><strong>关于 Foralumab</strong></p>
<p>Foralumab 是一种完全人源的抗 CD3 单克隆抗体，是一种生物药物候选药物，已显示在鼻用给药时能够刺激 T 调节细胞。目前，已有 14 名非活动性继发性进展性多发性硬化症（na-SPMS）患者在一个开放标签的中型扩展接入（EA）项目（NCT06802328）中接受了给药，所有患者在 6 个月内均观察到疾病改善或稳定。此外，鼻用 foralumab 目前正在进行一项针对非活动性继发性进展性多发性硬化症患者的 2a 期随机双盲安慰剂对照多中心剂量范围试验（NCT06292923）。</p>
<p>Foralumab 是目前唯一在临床开发中的完全人源抗 CD3 单克隆抗体（mAb）。鼻用 foralumab 的免疫调节代表了治疗神经炎症和神经退行性人类疾病的新途径。[1],[2]</p>
<p><strong>关于 Tiziana Life Sciences</strong></p>
<p>Tiziana Life Sciences 是一家临床阶段的生物制药公司，开发突破性疗法，利用变革性的药物递送技术实现免疫疗法的替代给药途径。Tiziana 的创新鼻用方法有潜力在疗效、安全性和耐受性方面提供比静脉（IV）给药更好的改善。Tiziana 的主要候选药物鼻用 foralumab 是目前唯一在临床开发中的完全人源抗 CD3 单克隆抗体，已在目前的研究中显示出良好的安全性和临床反应。Tiziana 的替代免疫疗法技术已获得专利，多个申请正在审理中，预计将允许广泛的产品线应用。</p>
<p>有关 Tiziana Life Sciences 及其创新疗法管线的更多信息，请访问 www.tizianalifesciences.com。</p>
<p>如需进一步咨询：</p>
<p><strong>Tiziana Life Sciences Ltd</strong></p>
<p>Paul Spencer，业务发展和投资者关系</p>
<p>+44 (0) 207 495 2379</p>
<p>电子邮件：info@tizianalifesciences.com</p>
<p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
<p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qVXlNU00zTXpJeU9UVTVJekl4TWpNNE9EVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qVXlNU00zTXpJeU9UVTVJekl4TWpNNE9EVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTFkNWIxZDMtYTU4Mi00NDgzLWIzZTctYTAzYzkwOWEyOTc3LTExMzU0NTYtMjAyNS0xMi0xNS1lbg==/tiny/Tiziana-Life-Sciences-Plc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTFkNWIxZDMtYTU4Mi00NDgzLWIzZTctYTAzYzkwOWEyOTc3LTExMzU0NTYtMjAyNS0xMi0xNS1lbg==/tiny/Tiziana-Life-Sciences-Plc.png"/></p>

TLSA

<p>Tiziana Life Sciences 宣布其首席执行官 Ivor Elrifi 购买了 163,400 股公司股票，使其总持股量增加至 357,848 股。Tiziana 是一家生物技术公司，正在开发用于治疗神经炎症疾病的鼻用 foralumab，这是一种完全人源化的抗 CD3 单克隆抗体。该公司正在进行这一创新疗法的临床试验，该疗法在非活动性继发性进展型多发性硬化症患者中显示出良好的效果</p>

<p>BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848.</p>
<div class="lb-trans"><p>波士顿，2025 年 12 月 15 日（环球新闻）—— Tiziana Life Sciences, Ltd.（纳斯达克：TLSA）（“Tiziana” 或 “公司”）是一家生物技术公司，正在开发突破性的免疫调节疗法，其主要开发候选药物为鼻用 foralumab，这是一种完全人源的抗 CD3 单克隆抗体。今天宣布其首席执行官 Ivor Elrifi 在公开市场购买了 163,400 股 Tiziana 普通股。这使得他目前购买的股票总数达到 357,848 股。</p>
</div><p><strong>About Foralumab</strong></p>
<div class="lb-trans"><p><strong>关于 Foralumab</strong></p>
</div><p>Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).</p>
<div class="lb-trans"><p>Foralumab 是一种完全人源的抗 CD3 单克隆抗体，是一种生物药物候选药物，已显示在鼻用给药时能够刺激 T 调节细胞。目前，已有 14 名非活动性继发性进展性多发性硬化症（na-SPMS）患者在一个开放标签的中型扩展接入（EA）项目（NCT06802328）中接受了给药，所有患者在 6 个月内均观察到疾病改善或稳定。此外，鼻用 foralumab 目前正在进行一项针对非活动性继发性进展性多发性硬化症患者的 2a 期随机双盲安慰剂对照多中心剂量范围试验（NCT06292923）。</p>
</div><p>Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]</p>
<div class="lb-trans"><p>Foralumab 是目前唯一在临床开发中的完全人源抗 CD3 单克隆抗体（mAb）。鼻用 foralumab 的免疫调节代表了治疗神经炎症和神经退行性人类疾病的新途径。[1],[2]</p>
</div><p><strong>About Tiziana Life Sciences</strong></p>
<div class="lb-trans"><p><strong>关于 Tiziana Life Sciences</strong></p>
</div><p>Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.</p>
<div class="lb-trans"><p>Tiziana Life Sciences 是一家临床阶段的生物制药公司，开发突破性疗法，利用变革性的药物递送技术实现免疫疗法的替代给药途径。Tiziana 的创新鼻用方法有潜力在疗效、安全性和耐受性方面提供比静脉（IV）给药更好的改善。Tiziana 的主要候选药物鼻用 foralumab 是目前唯一在临床开发中的完全人源抗 CD3 单克隆抗体，已在目前的研究中显示出良好的安全性和临床反应。Tiziana 的替代免疫疗法技术已获得专利，多个申请正在审理中，预计将允许广泛的产品线应用。</p>
</div><p>For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.</p>
<div class="lb-trans"><p>有关 Tiziana Life Sciences 及其创新疗法管线的更多信息，请访问 www.tizianalifesciences.com。</p>
</div><p>For further inquiries:</p>
<div class="lb-trans"><p>如需进一步咨询：</p>
</div><p><strong>Tiziana Life Sciences Ltd</strong></p>
<div class="lb-trans"><p><strong>Tiziana Life Sciences Ltd</strong></p>
</div><p>Paul Spencer, Business Development, and Investor Relations</p>
<div class="lb-trans"><p>Paul Spencer，业务发展和投资者关系</p>
</div><p>+44 (0) 207 495 2379</p>
<div class="lb-trans"><p>+44 (0) 207 495 2379</p>
</div><p>email: info@tizianalifesciences.com</p>
<div class="lb-trans"><p>电子邮件：info@tizianalifesciences.com</p>
</div><p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
<div class="lb-trans"><p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
</div><p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
<div class="lb-trans"><p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01qVXlNU00zTXpJeU9UVTVJekl4TWpNNE9EVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMjUyMSM3MzIyOTU5IzIxMjM4ODU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MTFkNWIxZDMtYTU4Mi00NDgzLWIzZTctYTAzYzkwOWEyOTc3LTExMzU0NTYtMjAyNS0xMi0xNS1lbg==/tiny/Tiziana-Life-Sciences-Plc.png" alt="" original-src="https://ml.globenewswire.com/media/MTFkNWIxZDMtYTU4Mi00NDgzLWIzZTctYTAzYzkwOWEyOTc3LTExMzU0NTYtMjAyNS0xMi0xNS1lbg==/tiny/Tiziana-Life-Sciences-Plc.png"/></p>

Tiziana Life Sciences 宣布其首席执行官购买公司股票 | TLSA 股票新闻